These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20148735)

  • 1. VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.
    Bidet A; Jais C; Puymirat E; Coste P; Nurden A; Jakubowski J; Nurden P
    Platelets; 2010; 21(2):94-100. PubMed ID: 20148735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
    Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
    Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet Vasodilator-Stimulated Phosphoprotein flow cytometry.
    von Beckerath N; Sibbing D; Jawansky S; Braun S; Morath T; Vogt W; Schömig A; Kastrati A
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):46-52. PubMed ID: 19823079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor.
    Pampuch A; Cerletti C; de Gaetano G
    Thromb Haemost; 2006 Dec; 96(6):767-73. PubMed ID: 17139371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel.
    Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L
    Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition.
    Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A
    Platelets; 2010; 21(7):563-70. PubMed ID: 20642320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
    Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
    Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study.
    Gurbel PA; Bliden KP; Butler K; Antonino MJ; Wei C; Teng R; Rasmussen L; Storey RF; Nielsen T; Eikelboom JW; Sabe-Affaki G; Husted S; Kereiakes DJ; Henderson D; Patel DV; Tantry US
    Circulation; 2010 Mar; 121(10):1188-99. PubMed ID: 20194878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring.
    Metzler H; Prüller F; Münch A; Primus G; Kainz J; Hödl R; Rehak P
    Eur J Anaesthesiol; 2010 Feb; 27(2):138-45. PubMed ID: 19593147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
    Tsantes A; Ikonomidis I; Papadakis I; Kottaridi C; Tsante A; Kalamara E; Kardoulaki A; Kopterides P; Kapsimali V; Karakitsos P; Lekakis J; Travlou A
    Platelets; 2012; 23(6):481-9. PubMed ID: 22646492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
    Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
    Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
    Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
    Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
    Pinto Slottow TL; Bonello L; Gavini R; Beauzile P; Sushinsky SJ; Scheinowitz M; Kaneshige K; Xue Z; Torguson R; Tantry U; Pichard AD; Satler LF; Suddath WO; Kent K; Gurbel P; Waksman R
    Am J Cardiol; 2009 Aug; 104(4):525-30. PubMed ID: 19660606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.